Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.41 |
| ▸ | CDK9 | P50750 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180652 | 0.81 | PPARG (0.52) | TNKSTNKS2CCNT1CDK9HTR1A | |
| SCHEMBL7759086 | 0.78 | PPARG (0.41) | TNKSTNKS2CCNT1CDK9HTR1A | |
| Hydrochloric Acid SCHEMBL6313945 | 0.75 | RECQL (0.52) | HTR1AMAPT | |
| SCHEMBL6068170 | 0.75 | DRD2 (0.52) | HTR1AMAPT | |
| SCHEMBL6068249 | 0.75 | DRD2 (0.55) | HTR7 | |
| SCHEMBL31348196 | 0.74 | CCNT1 (0.52) | TNKSTNKS2CCNT1CDK9HTR1A | |
| SCHEMBL31348259 | 0.74 | CCNT1 (0.52) | TNKSTNKS2CCNT1CDK9HTR1A | |
| SCHEMBL6177022 | 0.73 | MEN1 (0.51) | CCNT1CDK9HTR1AKCNH2PPARG | |
| SCHEMBL6179380 | 0.71 | PPARG (0.47) | CCNT1CDK9HTR1APARP1KCNH2 | |
| SCHEMBL2396688 | 0.71 | HTR1A (0.57) | CCNT1CDK9HTR1APARP1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7049330-B2 | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents | WYETH (US) | 2006-05-23 | — | — | US | claimed |
| US-20030139449-A1 | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents | WYETH (US) | 2003-07-24 | — | — | US | claimed |
| US-6518272-B2 | HT3 receptor agonists and antagonists; treatment of anxiety, depression, cognitive deficits, and prostate cancer | WYETH | 2003-02-11 | — | — | US | claimed |
| US-20020156075-A1 | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents | WYETH (FORMERLY AMERICAN HOME PRODUCTS CORPORATION) (US) | 2002-10-24 | — | — | US | claimed |
| US-7049330-B2 | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents | WYETH (US) | 2006-05-23 | — | — | US | disclosed |
| US-20030139449-A1 | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents | WYETH (US) | 2003-07-24 | — | — | US | disclosed |
| US-6518272-B2 | HT3 receptor agonists and antagonists; treatment of anxiety, depression, cognitive deficits, and prostate cancer | WYETH | 2003-02-11 | — | — | US | disclosed |
| US-20020156075-A1 | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents | WYETH (FORMERLY AMERICAN HOME PRODUCTS CORPORATION) (US) | 2002-10-24 | — | — | US | disclosed |
| US-6376494-B1 | USED IN THE TREATMENT OF ANXIETY AND DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139449-A1 | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents | HTR5A, MC5R, CHRNA5 | TNKS 1020/4885TNKS2 1536/4885CCNT1 2071/4885 |
| US-20020156075-A1 | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents | HTR5A, MC5R, CHRNA5 | TNKS 1020/4885TNKS2 1536/4885CCNT1 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.